South Street Advisors LLC Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

South Street Advisors LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 34.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 229,765 shares of the biopharmaceutical company’s stock after buying an additional 58,350 shares during the quarter. Halozyme Therapeutics accounts for about 1.7% of South Street Advisors LLC’s investment portfolio, making the stock its 28th largest position. South Street Advisors LLC owned approximately 0.18% of Halozyme Therapeutics worth $10,985,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in HALO. Cibc World Markets Corp purchased a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $558,000. Gallacher Capital Management LLC lifted its holdings in Halozyme Therapeutics by 54.1% during the fourth quarter. Gallacher Capital Management LLC now owns 6,526 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 2,291 shares in the last quarter. Royce & Associates LP lifted its holdings in Halozyme Therapeutics by 58.9% during the fourth quarter. Royce & Associates LP now owns 196,999 shares of the biopharmaceutical company’s stock valued at $9,419,000 after purchasing an additional 72,988 shares in the last quarter. CBIZ Investment Advisory Services LLC purchased a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Finally, Aurora Investment Counsel lifted its holdings in Halozyme Therapeutics by 8.6% during the fourth quarter. Aurora Investment Counsel now owns 35,118 shares of the biopharmaceutical company’s stock valued at $1,679,000 after purchasing an additional 2,768 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on HALO shares. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Benchmark reaffirmed a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Up 1.1 %

Shares of HALO opened at $62.95 on Tuesday. The stock has a market capitalization of $7.75 billion, a price-to-earnings ratio of 18.35, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53. The business’s 50 day simple moving average is $57.05 and its 200-day simple moving average is $54.63. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the transaction, the director now owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. The trade was a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.